|
|
|
| Effect of Ziprasidone on glucose and lipid metabolism in patients with schizophrenia |
| CHEN Yu-hong |
| First Ward of Department of Psychiatric, Yingkou Fourth People′s Hospital, Liaoning Province, Yingkou 115005, China |
|
|
|
|
Abstract Objective To explore the effect of Ziprasidone on glucose and lipid metabolism in patients with schizophrenia. Methods A total of 120 patients with schizophrenia who were treated in our hospital from December 2017 to December 2019 were selected and divided into a control group (n=60) and a study group (n=60) according to the random number table method. In the control group, olanzapine was used for treatment, and in the study group, Ziprasidone was adopted. The body mass index (BMI), fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h BG), fasting insulin (INS), insulin resistance index (HOMA-IR), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triacylglycerol (TG) of the two groups were measured before and 8-week after treatment. Results Before treatment,there were no significant differences in BMI, FBG, 2 h BG, INS, HOMAIR, TC, TG, LDL-C and HDL-C between the two groups (P＞0.05). The BMI, FBG, 2 h BG, INS, HOMA-IR, TC, TG and LDL-C of the control group were higher than those before treatment, the differences were statistically significant(P＜0.05). The difference of comparison on HDL-C before and after treatment in the control group was not statistically significant (P＞0.05). The differences in the comparisons on BMI, FBG, 2 h BG, INS, HOMA-IR, TC, TG, LDL-C and HDL-C before and after treatment in the study group were not statistically significant (P＞0.05). After treatment, the indicators of BMI, FBG, 2 h BG, INS, HOMA-IR, TC, TG and LDL-C in the study group were all lower than those in the control group, the differences were statistically significant (P＜0.05). There was no statistical difference in HDL-C between the two groups after treatment (P＞0.05). Conclusion Ziprasidone has no obvious influence on glucose and lipid metabolism in patients with schizophrenia. It is less likely to cause diabetes and glucose and lipid metabolism disorders in high safety and clinical applicability.
|
|
Received: 21 April 2020
|
|
|
|
| [1] |
潘虹，赵林，陈冬梅.齐拉西酮与氨磺必利治疗急性期精神分裂症的疗效及对糖脂代谢影响比较[J].临床合理用药杂志，2020，13（7）：3-5.
|
| [2] |
曹峰，谢渭根.奥氮平与齐拉西酮治疗精神分裂症的疗效及对糖脂代谢的影响[J].中华全科医学，2020，18（2）：217-219，232.
|
| [3] |
李志宏.齐拉西酮与氯丙嗪对精神分裂症患者代谢综合征的影响分析[J].中国医药指南，2020，18（1）：106.
|
| [4] |
罗海东，林荫，刘向来.经颅磁刺激联合齐拉西酮胶囊对精神分裂症患者代谢指标及血清神经营养因子水平的影响[J].中国医药，2019，14（12）：1886-1890.
|
| [5] |
郭晓曦.ICD-10 与DSM-5 诊断双相障碍的一致性比较[D].济宁：济宁医学院，2015.
|
| [6] |
王涵.小剂量齐拉西酮对奥氮平所致精神分裂症患者代谢障碍的干预[J].世界最新医学信息文摘，2017，17（44）：84，86.
|
| [7] |
肖涛，郑文静.齐拉西酮与奥氮平治疗早期精神分裂症的疗效及安全性比较研究[J].药品评价，2017，14（8）：53-55.
|
| [8] |
马德，李丽.齐拉西酮对首发精神分裂症患者糖脂代谢和血清泌乳素的影响[J].临床精神医学杂志，2017，27（1）：60.
|
| [9] |
周应兴.齐拉西酮和奥氮平对首发精神分裂症患者糖脂代谢的影响探析[J].世界最新医学信息文摘，2016，16（88）：90-91.
|
| [10] |
杨李雅，王晓莉，戴润珠.齐拉西酮与奥氮平对首发精神分裂症患者糖脂代谢的影响[J].转化医学电子杂志，2016，3（10）：57，59.
|
| [11] |
崔慧琪.齐拉西酮治疗老年脑器质性精神障碍的临床疗效[J].实用中西医结合临床，2019，19（3）：107-109.
|
| [12] |
魏玲，龚飞中，熊生杰，等.齐拉西酮与奥氮平对女性精神分裂症患者阴、阳性症状与内分泌代谢的影响[J].国际精神病学杂志，2019，46（1）：106-108，112.
|
| [13] |
卿王兵.为老年精神分裂症患者使用齐拉西酮与奥氮平进行治疗对其糖脂代谢影响的对比[J].当代医药论丛，2019，17（2）：22-23.
|
| [14] |
宋新虹，贺守彬.齐拉西酮治疗奥氮平致体重增加精神分裂症患者的效果和安全性[J].中国当代医药，2019，26（1）：91-93，97.
|
| [15] |
洪二郎，常凤坤.齐拉西酮胶囊联合奥氮平治疗高龄精神分裂症患者疗效及对精神症状、糖脂代谢和BMI 的影响[J].中国医药科学，2018，8（24）：38-40，68.
|
| [16] |
沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症疗效及糖脂代谢的影响观察[J].医学信息，2018，31（6）：130-132.
|
| [17] |
Mischoulon D，Shelton RC，Baer L，et al.Ziprasidone augmentation of escitalopram for major depressive disorder：cardiac，endocrine，metabolic，and motoric effects in a randomized，double-blind，placebo-controlled study[J].J Clin Psychiatry，2017，78（4）：449-455.
|
| [18] |
Park Y，Hernandez-Diaz S，Bateman BT，et al.Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes[J].Am J Psychiatry，2018，175（6）：564-574.
|
|
|
|
